Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2016-10-27 Capital/Financing Update
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated October 26, 2016, by Ritter Pharmaceuticals, Inc. It reports the entry into a material definitive agreement, specifically an underwriting agreement for a public offering of common stock. The document details the terms of the offering, including the number of shares, price, gross proceeds, and use of proceeds. It also references exhibits such as the underwriting agreement and legal opinion. Form 8-K filings are current reports used to announce major events that shareholders should know about, including capital raising activities. This filing is not a full annual or quarterly report, nor is it an earnings release or management discussion. It is a capital/financing update regarding a stock offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about the financing event, not just an announcement or certification, supporting a high confidence level.
2016-10-27 English
Capital/Financing Update 2016
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement and accompanying prospectus related to an offering of common stock by Ritter Pharmaceuticals, Inc. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and other related disclosures. The document references SEC registration statements and filings, including Form S-3 and mentions the Securities Act of 1933 and the Securities Exchange Act of 1934. This type of document is a capital raising disclosure used to inform investors about a new share issuance. It is not a financial report, earnings release, or management discussion, but rather a detailed capital/financing update related to a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback, but a substantive financing document.
2016-10-26 English
PRIMARY DOCUMENT
Director's Dealing
2016-10-26 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content specifically provides preliminary financial data for the quarter ended September 30, 2016, including estimated cash, cash equivalents, and liabilities. It explicitly states that the data is preliminary and unaudited, and it is not a full financial report but an update on financial condition. The document does not contain comprehensive financial statements or detailed analysis typical of an Interim/Quarterly Report (IR). Instead, it is a regulatory filing to disclose material financial information promptly. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not fit the criteria for a full interim report or earnings release.
2016-10-25 English
4 Filing
Director's Dealing
2016-10-25 English
SC 13G
Major Shareholding Notification
2016-10-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.